These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 12509398)

  • 1. Postmenopausal hormone therapy and change in mammographic density.
    Greendale GA; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Ursin G
    J Natl Cancer Inst; 2003 Jan; 95(1):30-7. PubMed ID: 12509398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.
    Greendale GA; Reboussin BA; Sie A; Singh HR; Olson LK; Gatewood O; Bassett LW; Wasilauskas C; Bush T; Barrett-Connor E
    Ann Intern Med; 1999 Feb; 130(4 Pt 1):262-9. PubMed ID: 10068383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
    Ursin G; Palla SL; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Greendale GA
    J Clin Oncol; 2004 Jul; 22(14):2842-8. PubMed ID: 15254051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk.
    Byrne C; Ursin G; Martin CF; Peck JD; Cole EB; Zeng D; Kim E; Yaffe MD; Boyd NF; Heiss G; McTiernan A; Chlebowski RT; Lane DS; Manson JE; Wactawski-Wende J; Pisano ED
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy.
    Crandall CJ; Karlamangla A; Huang MH; Ursin G; Guan M; Greendale GA
    Arch Intern Med; 2006 Aug 14-28; 166(15):1578-84. PubMed ID: 16908790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
    Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
    JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast tenderness after initiation of conjugated equine estrogens and mammographic density change.
    Crandall CJ; Aragaki AK; Cauley JA; McTiernan A; Manson JE; Anderson GL; Wactawski-Wende J; Chlebowski RT
    Breast Cancer Res Treat; 2012 Feb; 131(3):969-79. PubMed ID: 21979747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women.
    Barrett-Connor E; Slone S; Greendale G; Kritz-Silverstein D; Espeland M; Johnson SR; Waclawiw M; Fineberg SE
    Maturitas; 1997 Jul; 27(3):261-74. PubMed ID: 9288699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
    JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens.
    Lundström E; Wilczek B; von Palffy Z; Söderqvist G; von Schoultz B
    Climacteric; 2001 Mar; 4(1):42-8. PubMed ID: 11379377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increases in serum estrone sulfate level are associated with increased mammographic density during menopausal hormone therapy.
    Crandall CJ; Guan M; Laughlin GA; Ursin GA; Stanczyk FZ; Ingles SA; Barrett-Connor E; Greendale GA
    Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1674-81. PubMed ID: 18628419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of estrogen with and without progestin on urinary incontinence.
    Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
    JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.
    Espeland MA; Rapp SR; Shumaker SA; Brunner R; Manson JE; Sherwin BB; Hsia J; Margolis KL; Hogan PE; Wallace R; Dailey M; Freeman R; Hays J;
    JAMA; 2004 Jun; 291(24):2959-68. PubMed ID: 15213207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo.
    Murkes D; Lalitkumar PG; Leifland K; Lundström E; Söderqvist G
    Gynecol Endocrinol; 2012 Oct; 28 Suppl 2():12-5. PubMed ID: 22834417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
    Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial.
    McTiernan A; Chlebowski RT; Martin C; Peck JD; Aragaki A; Pisano ED; Wang CY; Johnson KC; Manson JE; Wallace RB; Vitolins MZ; Heiss G
    J Clin Oncol; 2009 Dec; 27(36):6135-43. PubMed ID: 19901118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women.
    Koh KK; Jin DK; Yang SH; Lee SK; Hwang HY; Kang MH; Kim W; Kim DS; Choi IS; Shin EK
    Circulation; 2001 Apr; 103(15):1961-6. PubMed ID: 11306524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.